In this study, we evaluated the potency of a human papillomavirus (HPV) virus-like particle
(VLP)-based vaccine at generating HPV type 11 (HPV-11)-specific cellular and humoral …

Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and
16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus …

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV …

Human papillomavirus-like particles (HPV VLP) are candidate vaccines that have shown to
be efficacious in reducing infection and inducing robust antiviral immunity. Neutralizing …

To determine the systemic cytokine pattern induced by vaccination with human
papillomavirus (HPV) L1 virus-like particles (VLP), we analyzed 22 different cytokines in …

The causal association between papillomavirus (HPV) infection and cervical cancer has
been demonstrated; the development of a prophylactic vaccine to protect against HPV …

ContextViruslike particle human papillomavirus (HPV) vaccines were designed to prevent
HPV infection and development of cervical precancers and cancer. Women with oncogenic …

A post hoc analysis was performed using combined data from two Phase I tolerability/
immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 …

Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and
HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the …

Abstract Background. The quadrivalent (types 6, 11, 16, and 18) human papillomavirus
(HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and …